Tirzepatide Improves Liver Biomarkers in Type 2 Diabetes Patients
Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefits of GLP-1/GIP dual agonism alongside metabolic improvements.
Quick Facts
What This Study Found
Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefits of GLP-1/GIP dual agonism alongside metabolic improvements.
Key Numbers
16 patients enrolled, 13 completed 48 weeks. Tirzepatide started at 2.5 mg weekly with dose adjustments at physician discretion.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefi
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.
- Published In:
- Hepatology research : the official journal of the Japan Society of Hepatology, 55(10), 1346-1352 (2025)
- Authors:
- Arai, Taeang, Atsukawa, Masanori, Nagao, Chikako, Yamada, Zento, Rokugo, Takahiro, Suzuki, Kenta, Kitamura, Michika, Higashi, Tetsuyuki, Koyano, Kaori, Hasegawa, Yuta, Kawano, Tadamichi, Ono, Hiroki, Yoshida, Yuji, Okubo, Tomomi, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Nagao, Mototsugu, Iwabu, Masato, Iwakiri, Katsuhiko
- Database ID:
- RPEP-09964
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Tirzepatide treatment improved hepatic biomarkers in T2D patients, demonstrating liver health benefits of GLP-1/GIP dual agonism alongside metabolic improvements.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09964APA
Arai, Taeang; Atsukawa, Masanori; Nagao, Chikako; Yamada, Zento; Rokugo, Takahiro; Suzuki, Kenta; Kitamura, Michika; Higashi, Tetsuyuki; Koyano, Kaori; Hasegawa, Yuta; Kawano, Tadamichi; Ono, Hiroki; Yoshida, Yuji; Okubo, Tomomi; Hayama, Korenobu; Nakagawa-Iwashita, Ai; Itokawa, Norio; Kondo, Chisa; Nagao, Mototsugu; Iwabu, Masato; Iwakiri, Katsuhiko. (2025). Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.. Hepatology research : the official journal of the Japan Society of Hepatology, 55(10), 1346-1352. https://doi.org/10.1111/hepr.14241
MLA
Arai, Taeang, et al. "Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.." Hepatology research : the official journal of the Japan Society of Hepatology, 2025. https://doi.org/10.1111/hepr.14241
RethinkPeptides
RethinkPeptides Research Database. "Effect of Tirzepatide Treatment on Hepatic Biomarkers in Pat..." RPEP-09964. Retrieved from https://rethinkpeptides.com/research/arai-2025-effect-of-tirzepatide-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.